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Prophylactic Treatment of Seasonal Affective Disorder
(SAD) by Using Light Visors: Bright White or
Infrared Light?
Ybe Meesters, Domien G.M. Beersma, Antoinette L. Bouhuys,
and Rutger H. van den Hoofdakker
Background: Thirty-eight patients with SAD participated
in a light visor study addressing two questions.
1. Can the development of a depressive episode be pre-
vented by daily exposure to bright light started before
symptom onset in early fall and continued throughout
the winter?
2. Does the light have to be visible in order to have
beneficial effects?
Methods: Three groups participated in the study: I (n 5
14) received bright white light (2500 lux); II, (n 5 15)
received infrared light (0.18 lux); III (n 5 9, control
group) did not receive any light treatment at all.
Results: Infrared light is just as effective as bright white
light. Both are more effective than the control condition.
Conclusions: Light visors can be effectively used to
prevent the development of SAD. The fact that exposure to
infrared light was as effective as exposure to bright white
light questions the specific role of visible light in the treat-
ment of SAD. Biol Psychiatry 1999;46:239–246 © 1999
Society of Biological Psychiatry
Key Words: Seasonal affective disorder, prophylactic
treatment, light treatment, light visor
Introduction
Seasonal affective disorder (SAD, winter type) is asyndrome recurring almost every year, with symptoms
in autumn and winter, followed by a complete recovery
every spring and summer (Rosenthal et al 1984). Light
therapy has been shown to be a very effective treatment
(Terman et al 1989; Tam and Lam 1995). Because of the
almost predictable course of the syndrome, research was
performed to find a way to prevent the winter symptoms.
Light exposure at an early stage of a depressive episode
can prevent the emerging winter depression (Meesters et al
1993). Terman et al (1994) were unable to replicate these
findings but found that a subsequent episode of winter
depression was postponed by light therapy administered
after the first signs of a depressive episode. Light treat-
ment administered at a time before the winter season
(when the patients were free of symptoms) was ineffec-
tive, however (Meesters et al 1994). This study presents
the results of a design where patients used light visors at
home in the winter season. This is in line with our earlier
studies on light treatment and the possible prevention of
winter depression.
Light visors are portable head-mounted devices, which
have been shown to be successful in the treatment of
winter depression (McIntyre et al 1990; Ravaris et al 1994;
Rosenthal et al 1993; Joffe et al 1993; Stewart et al 1990;
Levitt et al 1994, 1996; Teicher et al 1995). The reported
response rates in these studies ranged from 36% to 58%.
Stewart et al (1990) and Levitt et al (1996) did not find any
differences between the treatment responses to a light
visor and a conventional light box. When used as a
maintenance therapy after successful intervention by
means of light boxes, light visors induced the same
response level as light boxes (Clark et al 1996).
The mechanisms underlying the effects of light treat-
ment in SAD are still unclear. The response to light
treatment may be a placebo effect (Eastman 1990). Light
visor treatment has been shown to be effective for a
variety of bright white light intensities (Joffe et al 1993;
Rosenthal et al 1993; Levitt et al 1994) and colors (Teicher
et al 1995). Levitt et al (1994) used red light (660 nm)
from a light-emitting diode in a head-mounted device and
did not find any differences between the therapeutic
responses to light with intensities of 4106 lux and 96 lux.
In the study of Teicher et al (1995), it was found that the
response to low-intensity red light (.600 nm) was at least
equal to the response to bright white light. In extrapolation
of those findings, we raised the question of whether it is
necessary for the light to be visible to achieve beneficial
From the Academic Hospital Groningen (YM); and University of Groningen
(DGMB, ALB, RHvdH), Groningen, The Netherlands.
Address requests for reprints to Y. Meesters, PhD, Academic Hospital Groningen,
Department of Biological Psychiatry, PO Box 30001, 9700 RB Groningen, The
Netherlands.
Received October 10, 1997; revised April 7, 1998; revised July 29, 1998; accepted
July 31, 1998.
© 1999 Society of Biological Psychiatry 0006-3223/99/$20.00
PII S0006-3223(98)00252-2
effects. Exposure to infrared light (.700 nm) might also
be effective.
In view of these considerations, a light visor study was
designed addressing the following questions.
1. Can the development of depressive episodes be
prevented by daily exposure to bright light initiated
before symptom onset in the early fall and continued
throughout the winter season?
2. Does the light have to be visible to have beneficial
effects?
Methods and Materials
Fifty SAD out-patients gave their consent to take part in the
study (30 in the winter season of 1993-94; 20 in the winter of
1994-95). All were free of drugs and diagnosed as suffering from
seasonal affective disorder according to the criteria of Rosenthal
and co-workers (1984), and seasonal pattern according to the
DSM-III-R (APA, 1987) and suffered from regular annual
depressions. The time of consent was September and the study
started in October. At that time, four patients had already
developed a depression and were unable to take part in the
experiment for that reason. The remaining 46 patients were
assigned to one of three conditions.
Condition 1: Exposure to bright white visor light (BL; n 5
14; 2 men, mean age 41.0 yrs 6 12.7; 12 women, mean age
39.5 yrs 6 9.3)
Condition 2: Exposure to infrared light (IR) by means of a
light visor equipped with a Kodak Wratten filter (type 89b,
720 nm) (n 5 15; 5 men, mean age 35.4 yrs 6 6.9; 10
women, mean age 36.6 yrs, 6 4.9)
Condition 3: No light exposure (CON); no light visor pro-
vided (n 5 9; 4 men, mean age 47.5 yrs 6 7.0; 5 women,
mean age 39.4 yrs 6 8.0)
Figure 1 shows the spectral power distribution of the two light
sources.
The first winter, equal numbers of patients were randomly
assigned to all three conditions. Because of the limited number of
participants we were able to recruit the second winter, we
decided to assign twice as many patients to each of the light
conditions as to the control condition. This assignment was also
random.
All patients were known SAD patients who had had successful
conventional light treatments in previous winter seasons. Evi-
dently, the patients in the untreated control group ran a consid-
erable risk of becoming depressed. This group, therefore, repre-
sented a kind of waiting-list control group. From previous
studies, it is known that not every SAD patient becomes
depressed every year (Thompson, 1989; Meesters et al 1993). It
is therefore important to collect data concerning this type of a
waiting-list control group. Statistically, the subjects of the three
groups did not differ in age, gender, or season of participation
(ANOVA).
Eight subjects dropped out during the experiment for the
following reasons: one failed to wear the light visor; one started
using medication; one patient in the control condition was treated
with light therapy at her own emphatic request (light box) after
reaching a BDI score $13 in 1 week instead of 2 weeks; another
five patients stopped participating because of reasons unrelated
to their illness, such as a lack of motivation to keep scoring
self-rating scales when in a healthy mental state, moving to a new
home, etc. In the bright light condition, four subjects dropped
out, in the infrared condition, three, and one subject in the control
condition. We do not have systematic information on the
drop-outs for the rest of the season.
The light visors were manufactured by Bio Brite Inc. (Be-
thesda, MD, USA). They contained two krypton incandescent
bulbs powered by a rechargeable battery. Subjects used them 30
min daily (except on Saturdays and Sundays) between 6:00 and
9:00 AM.
This study was a field study. Light treatment was part of every
day life. Participants were asked to choose their own fixed
treatment time in their daily routine. They registered this time
during the season.
Mood was assessed weekly by means of the Beck Depression
Inventory (BDI, 21-item version, Beck et al, 1961; 1979), and a
translated version of the SIGH-SAD-SR (29-item version, Wil-
liams et al 1992). Patients reaching a BDI score of $13 in 2
consecutive weeks were considered to have developed a depres-
sive episode. If patients reached a BDI score of $22, they were
considered to be severely depressed, and left the study at that
moment. They were offered light treatment in the clinic. As
statistical procedure, the Kaplan Meier Survival Analysis was
used (Kaplan and Meier 1958).
In our first studies we used the BDI (Beck et al 1961; 1979) to
assess the severity of depression. Terman and co-workers (1994)
compared the scores of the BDI with scores of the SIGH-
SAD-SR (Williams et al 1992) and found some differences.
Figure 1. The spectral power distribution of bright white light
and infrared light from a light visor.
240 Y. Meesters et alBIOL PSYCHIATRY
1999;46:239–246
Patients with relatively mild depression scores according to the
BDI appeared to be more severely depressed on the basis of the
SIGH-SAD-SR scores. Data of the present study allow compar-
ison of the scores of the BDI and the SIGH-SAD-SR. Following
Terman and co-workers (1994), we assumed that a SIGH-
SAD-SR score of $20 is equivalent to a BDI score of $13 and




Thirty-six percent (5 out of 14) of the patients in the bright
light condition developed a depression (one of them
severe), against 7% (1 out of 15) in the infrared condition
(severe) and 78% (7 out of 9) in the control condition (6 of
them severe). Figure 2A shows the average BDI scores per
condition.
According to a Kaplan Meier Survival Analysis, the
results in the infrared light condition were significantly
better than those in the bright white light condition
(Breslow stat.: 4.38; df 5 1; p 5 0.04). Similarly, the
results in the IR condition were better than the results in
the control condition (Breslow stat.: 17.81; df 5 1; p 5
0.000). Finally, there was a statistically significant dif-
ference between the results of the bright white light
condition and the results of the control condition in favor
of the light condition (Breslow stat.: 8.85; df 5 1; p 5
0.03) (Figure 3A).
In the IR condition, only one subject became depressed.
Therefore, it was not possible to perform multiple pairwise
comparisons. No significant correlations (Spearman) were
found between age or gender on the one hand, and the
outcome measures on the other.
SIGH-SAD-SR
When we used the SIGH-SAD-SR criterion, the results
were slightly different. Forty-three percent of the patients
(6 out of 14) in the bright light condition became de-
pressed (one of them severe), 33% (5 out of 15) in the
infrared condition (one of them severe) and 67% (6 out of
9) in the control condition (3 severe) (Figure 2B).
Kaplan Meier Survival Analysis showed no difference
between the results of the two light conditions. The results
in the infrared condition were significantly better than
those in the control condition (Breslow stat.: 5.55; df 5 1;
p 5 0.02). The results of the bright white light condition
showed a tendency to be better than those in the control
condition (Breslow stat.: 3.21; df 5 1; p 5 0.07) (Figure
3B).
BDI Versus SIGH-SAD-SR
Six patients reached the SIGH-SAD-SR criterion but
failed to reach the BDI criterion for recurrence of a
depressive episode. Two patients who reached the BDI
criterion did not reach the SIGH-SAD-SR criterion. The
larger number of patients who reached the SIGH-SAD-SR
Figure 2. The course of mood during the winter season as
assessed by means of the BDI (A) and the SIGH-SAD-SR (B).
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criterion is mainly due to their scores on the atypical
symptom items in that questionnaire. These symptoms are
not assessed by means of the BDI. Thirteen subjects in this
study reached our BDI criterion for depression. Ten of
them (77%) had a score of $5 on the atypical score
section of the SIGH-SAD-SR.
Timing
At the end of the two winter seasons it became clear that
there was a difference between the two groups in the times
of day they had used the light visor. The BL group started
light exposure at a mean time of 7:55 AM, the IR group at
7:10 AM. This difference is statistically significant (two-
tailed t test: 2.64, p 5 0.014; see Figure 4).
Subjects who became depressed according to the BDI
criterion were offered light treatment by means of light
boxes in the out-patient clinic of the hospital. In some
subjects, the depression seemed to have come about by
events unrelated to the seasons. The father of one of the
subjects in the bright light condition died that winter
season, while at the same time her own business was going
into bankruptcy. A subject in the infrared condition
became depressed after his wife suddenly left him. These
kind of life events cannot be avoided in a field study. On
the other hand, it is unlikely that the change of mood
induced by these events can be treated with light. From the
other 11 subjects who became depressed, 6 received light
treatment and responded successfully. These 6 subjects all
participated in the waiting-list control group. The other 5
subjects did not accept the offer of light treatment and
stayed depressed for 2, 2, 2, 4 and 5 weeks (with BDI
scores ranging from 13 to 17), respectively.
Figure 3. The survival curves based on the BDI criterion (A) and
the SIGH-SAD-SR criterion (B).
Figure 4. The mean time schedule, compared to sun-up times, of
the bright white and infrared light conditions with patients
wearing light visors during the winter season.




This study demonstrates that SAD patients wearing a
light-emitting visor in winter develop fewer symptoms
than waiting-list control subjects. We were unable to settle
the question of whether these results should be interpreted
in terms of prevention of symptoms, or maintenance
therapy. We do not see how we can distinguish these
interpretations, and have pragmatically chosen the term
prophylactic treatment for our approach.
A light visor emitting infrared light seems to provide at
least as much protection as a light visor emitting bright
white light. This finding is in line with the data of Teicher
and colleagues (1995), who failed to find a statistically
significant difference between the response to a light visor
with white light (600 lux) and a light visor with dim red
light (. 600 nm, 30 lux). The fact that both light visor
conditions are more effective than the control condition,
leads to the conclusion that light visor treatment can be
used as a prophylactic intervention for SAD patients.
The possibility of using light treatment as a prophylactic
tool was also reported recently by Partonen and Lo¨nnqvist
(1996) and Clark and co-workers (1996). Although the
course of the symptoms is significantly better in the
treatment conditions than in the control condition, this
does not mean that the present design provides optimal
prophylaxis. Not all patients remained symptom-free dur-
ing the winter season. In the bright light condition,
according to the BDI scores, 36% of the participants
became depressed and in the IR condition 7%. According
to the SIGH-SAD-SR, even more participants reached the
criterion of depression (BL 43% and IR 33%). In both
conditions, one participant became severely depressed.
Our data are in line with those found in a comparable
study in which 28% of the subjects became depressed in
spite of prophylactic exposure to light (Kjellman et al
1997).
The relatively high number of depressive episodes
occurring in the light conditions is unexpected. A 5-day
light-box treatment applied at the first signs of a depres-
sive episode was previously shown to prevent a severe
depressive episode during the remaining part of the winter
season (Meesters et al 1993). Since the present light visor
treatment started before symptom onset and so covered the
phase of an emerging depression, an equal preventive
potential would be expected. Furthermore, many light-box
studies have demonstrated that an average treatment pe-
riod of 4 to 5 days usually suffices to induce a substantial
therapeutic response (Meesters et al 1995). Following this
line of reasoning, the continued application of the light
visor should have been sufficient to suppress the emerging
depression in all patients. Apparently, there are differences
in efficiency between our previous light-box treatment and
the present light visor treatment. One of the differences is
the fact that in our earlier studies light boxes were applied
in the out-patient clinic whereas the light visors in this
study were used at home. This might be an important
aspect. Obviously, patients treated clinically by an expert
receive more attention and perceive more security.
Spectral Properties of Light
In our two light visor conditions the light spectrum differs
(.400 nm versus .720 nm), while the therapeutic re-
sponses do not. The SAD literature on the therapeutic
significance of the spectral properties of light is confusing.
We list the studies in this area. Teicher et al (1995) found
no differences between the results of white and dim red
light visor treatment, but Brainard and co-workers (1990),
using light boxes, reported a superiority of white light over
blue or red light in a study comparing the effects of
different wavelengths. Also using light boxes, Oren et al
(1991) found green light to be superior to red light, while
Rice and al (1991) concluded that green light was less
effective than full spectrum light. No difference in re-
sponse was found to treatment with cool white light and
broad spectrum fluorescent light of light boxes (Bielski et
al 1992). Lam and colleagues (1992) observed that the
ultraviolet part of the spectrum did not increase the
antidepressant response to light treatment using light
boxes. Avery and co-workers (1994) reported the superi-
ority of white over red light in a study on the effects of
dawn simulation. Obviously, the data on the spectral
sensitivity of SAD patients are inconsistent. Theoretically,
it is possible that each kind of light source used has its own
optimal spectral composition, so we cannot compare the
results of different wavelengths emitted by different light
sources. Since Stewart and colleagues (1990) and Levitt et
al (1996) found no difference in therapeutic response
when comparing the effects of exposure to light of light
boxes with the effects of exposure to the light of light
visors, we do not believe that that is very plausible.
The finding that the effects of the two light treatment
conditions did not differ, raises some doubts about the
assumption that the perception of light plays a significant
role in the therapeutic mechanism that is responsible for
the results. Can we expect IR light to play any role at all?
Inoue´ and Kabaya (1989) reviewed the effects of far
infrared radiation (4 to 16 mm) and concluded that these
rays are “biologically active” in various ways. Almost
every light fixture produces light with an infrared compo-
nent. So, our data indicate that, if light is crucial to the
response, it must be that component which is crucial.
However, infrared light is beyond the visible range of the
spectrum. The 720 nm filter in our light visor still
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transmitted some visible light. However, its visibility was
virtually negligible (0.18 lux). The conclusion of this
study might therefore be that the perception of light does
not play a role in the therapeutic mechanism. Infrared
might be effective through pathways other than those
involved in perception.
Circadian Mechanisms
The effect of low-intensity red light on the human circa-
dian pacemaker has recently been demonstrated by Zeitzer
et al (1995). Exposure to nocturnal dim red light creates a
phase advance comparable to the phase advance after
exposure to white light. This finding would be consistent
with the possibility that the circadian pacemaker plays a
role in the mechanism underlying the effects of light
therapy. But even when the effects are induced by invis-
ible light, this kind of interpretation would be inconsistent
with other studies that show that therapeutic effects of
light are unrelated to the timing of light exposure (Wirz-
Justice et al 1993; Meesters et al 1995). Curiously enough,
though, the participants in the IR condition selected the
time of light exposure about 1 hour earlier than the
participants in the bright light condition (Figure 4). At that
time, the circadian pacemaker is thought to respond to
light pulses with a larger phase advance than it does 1 hour
later (Jewett et al 1991; Minors et al 1991). So, if, in fact,
phase shifts of the circadian pacemaker are involved in the
therapeutic response, this difference in time selection
might explain why the response to IR light is slightly
superior to the response to bright white light. However, it
should be noted that the smallest light intensity for which
phase responses of the pacemaker has been demonstrated
in humans is 180 lux (Boivin et al 1996) while our IR light
contained only 0.18 lux. It should also be remarked that,
although phase shifts are seen as a marker of the effect of
light on the circadian system, Amir and Stewart (1996)
showed that phase shifts can also be induced by a
conditioned stimulus. Obviously, the role of the circadian
system is far from clear.
In addition, it is not clear what part of the visual system
receives the input signal to the circadian pacemaker. In
animal studies the presence of photopigments in the retina
was manipulated. In genetically manipulated mice, which
only had cone cells within a restricted area of the retina,
and no rod cells at all, there still was a normal circadian
response to light (Garcia-Fernandez et al 1995; Argamaso
et al 1995). These cone cells degenerate with aging.
However, circadian responses to light still appeared in
aged mice with retinal degeneration (Provencio et al
1994). Whether, and in what way, the conclusions of this
experimental approach in mice can be generalized to
humans is unclear.
Ise et al (1987) described that blood flow can be
stimulated by means of far infrared radiation (4 to 16 mm).
Although far infrared differs from infrared light, the
present results are interesting when considered together
with the recent hypothesis of Oren (1996), who states that
blood possibly plays a role as messenger of the effects of
light on the brain. The infrared light in the dusk and dawn
periods are thought to function as a kind of trigger for a
circadian switch. Our data would seem to fit with this
hypothesis that IR light can influence the circadian system
and possibly the course of mood. Taken together, the
considerations mentioned demonstrate that little is known
about the circadian mechanism involved in the effects of
light treatment.
Other Mechanisms
Other mechanisms may explain the beneficial treatment
effects in SAD patients. Geerts and co-workers (1995)
found evidence for the assumption that behavioral pro-
cesses during the interaction between patients and inter-
viewers measured prior to treatment may play a role.
Bouhuys et al (1994) found that some cognitions as
assessed in the autumn are involved in the timing of a new
SAD episode. Expectations and cognitions may also have
played a role in the present study. Unfortunately, we did
not assess the subjects’ expectations about the therapeutic
potential of the light fixtures at the beginning of the study,
and we did not assess cognitions about the significance of
light and darkness for their mental well-being. Wearing a
light visor (during the winter for 5 days/week) implies that
patients are actively engaged in protecting themselves
from depression. Non-SAD depressed patients benefit
from self-help techniques, where they also take an active
part in their treatment (Gould and Clum 1993). Therefore,
patients’ active involvement with concomitant cognitions
and expectations, rather than the exposure to light, may
explain why the two light visor treatments are superior to
the control condition.
It is still possible that placebo effects entirely account
for the therapeutic outcome. Compared to a light-box, a
light visor looks like an “ingenious” fixture, and the
infrared light makes it even more special. These effects
might account for the results (Eastman 1990). This line of
reasoning is consistent with the fact that until now no
dose-response relationship has been observed in light visor
studies (Joffe et al 1993; Teicher et al 1995; Rosenthal et
al 1993; Levitt et al 1994). In an experiment using an
inactivated ion-generator to treat SAD patients, Eastman
and co-workers (1992) reported positive results, indicating
that placebo treatments are effective in SAD and that the
results are similar to those of light treatment. In a study
comparing the results of exposure to a light box and a
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head-mounted light fixture, both in a version with visible
light and a version without any light, Levitt et al (1996)
did not find a statistically significant difference between
the four conditions. Recently, Eastman and colleagues
(1996) claimed that a 4-week period of light treatment is
more effective than a placebo. Yet, the groups in that study
only differed with respect to the numbers of patients who
reached a remittance criterion, but not with respect to the
final treatment outcome after 4 weeks. Richter et al (1992)
found that the effects of real morning light were not
different from those of imaginary morning light immedi-
ately after the treatment. However, 10 days after treatment,
real light turned out to be superior. Considering this area
of research makes it clear that the issue of the placebo
effects of light treatment has not been settled yet.
A final topic to be discussed is the comparison of BDI
criterion for depression and the SIGH-SAD-SR criterion.
In this study, 17 out of 38 subjects became depressed
according to the SIGH-SAD-SR criterion and 13 accord-
ing to the BDI criterion. For a psychometric comparison of
the two questionnaires, the sample size is too small.
Nevertheless, our data are consistent with the statement of
Terman et al (1994) that the BDI is less sensitive in
detecting a depressive episode in SAD patients than the
SIGH-SAD-SR.
In conclusion, the present study demonstrates that
visible light is not a prerequisite for the therapeutic
response of SAD patients to light treatment. Whether IR
light is a critical therapeutic factor remains to be investigated.
We are grateful to J.S. Borger for her improvement of the English of the
manuscript and to Bio Bright Inc., Bethesda MD, for their support
(equipment).
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